Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis

Overview

Journal In Vivo

Specialty Oncology

Date 2018 Feb 25

PMID 29475923

Citations 3

Authors

Szymon Darocha

Michal Wilk

Anna Walaszkowska-Czyz

Jaroslaw Kepski

Rafal Manczak

Marcin Kurzyna

Adam Torbicki

Sebastian Szmit

Affiliations

Soon will be listed here.

Abstract

Background: Pericardial effusion is associated with high mortality in oncology. The etiology of infectious pericarditis and iatrogenic effects of previous radio-/chemotherapy may be always suspected, especially when a subsequent episode is observed.

Patients And Methods: The study included 17 hemodynamically-unstable patients with cancer due to recurrent pericardial bloody effusion after previous pericardiocentesis and analyzed survival determinants after intrapericardial chemotherapy with cisplatin.

Results: The mortality rate was not significantly associated with the level of N-terminal pro-B type natriuretic peptide, low hemoglobin (<12 g/dl), elevated white blood cell account (>10/μl), large volume (>1500 ml) and long duration (>8 days) of pericardial drainage, cardiac arrhythmias, positive culture test results nor fever occurring during cisplatin administration. Subsequent systemic anticancer therapy was the strongest factor determining a longer survival (hazard ratio(HR)=0.31, 95% confidence interval(CI)=0.11-0.9; p=0.03).

Conclusion: Efficacy of rescue intrapericardial chemotherapy with cisplatin is independent of parameters of hemodynamic instability and levels of inflammatory markers in recurrent pericardial effusion.

Citing Articles

Large Pericardial Effusion-Diagnostic and Therapeutic Options, with a Special Attention to the Role of Prolonged Pericardial Fluid Drainage.

Dybowska M, Szturmowicz M, Blasinska K, Gatarek J, Augustynowicz-Kopec E, Langfort R Diagnostics (Basel). 2022; 12(6).

PMID: 35741263 PMC: 9221585. DOI: 10.3390/diagnostics12061453.

Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.

Szmit S, Grela-Wojewoda A, Talerczyk M, Kufel-Grabowska J, Streb J, Smok-Kalwat J Sci Rep. 2020; 10(1):18481.

PMID: 33116159 PMC: 7595106. DOI: 10.1038/s41598-020-75614-4.

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.

Zaborowska-Szmit M, Krzakowski M, Kowalski D, Szmit S J Clin Med. 2020; 9(5).

PMID: 32349387 PMC: 7287714. DOI: 10.3390/jcm9051268.

References

Lestuzzi C, Lafaras C, Bearz A, Gralec R, Viel E, Buonadonna A . Malignant pericardial effusion: sclerotherapy or local chemotherapy?. Br J Cancer. 2009; 101(4):734-5. PMC: 2736808. DOI: 10.1038/sj.bjc.6605108. View

Tomkowski W, FILIPECKI S . Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer. Lung Cancer. 1997; 16(2-3):215-22. DOI: 10.1016/s0169-5002(96)00631-9. View

Imazio M, Spodick D, Brucato A, Trinchero R, Adler Y . Controversial issues in the management of pericardial diseases. Circulation. 2010; 121(7):916-28. DOI: 10.1161/CIRCULATIONAHA.108.844753. View

Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A . Indicators of poor prognosis of acute pericarditis. Circulation. 2007; 115(21):2739-44. DOI: 10.1161/CIRCULATIONAHA.106.662114. View

Vaitkus P, Herrmann H, LeWinter M . Treatment of malignant pericardial effusion. JAMA. 1994; 272(1):59-64. View

Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M . A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009; 100(3):464-9. PMC: 2658533. DOI: 10.1038/sj.bjc.6604866. View

Tomkowski W, Wisniewska J, Szturmowicz M, Kuca P, Burakowski J, Kober J . Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer. 2003; 12(1):53-7. DOI: 10.1007/s00520-003-0533-x. View

Bishiniotis T, Antoniadou S, Katseas G, Mouratidou D, Litos A, Balamoutsos N . Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). Am J Cardiol. 2000; 86(3):362-4. DOI: 10.1016/s0002-9149(00)00937-1. View

Imazio M, Mayosi B, Brucato A, Markel G, Trinchero R, Spodick D . Triage and management of pericardial effusion. J Cardiovasc Med (Hagerstown). 2010; 11(12):928-35. DOI: 10.2459/JCM.0b013e32833e5788. View

10.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special.... Eur J Heart Fail. 2016; 18(8):891-975. DOI: 10.1002/ejhf.592. View

11.

Imazio M, Demichelis B, Parrini I, Favro E, Beqaraj F, Cecchi E . Relation of acute pericardial disease to malignancy. Am J Cardiol. 2005; 95(11):1393-4. DOI: 10.1016/j.amjcard.2005.01.094. View

12.

Porte H, Finzi L, Metois D, Millaire A, Wurtz A . Pericardoscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg. 1999; 16(3):287-91. DOI: 10.1016/s1010-7940(99)00204-3. View

13.

Numico G, Cristofano A, Occelli M, Sicuro M, Mozzicafreddo A, Fea E . Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (Baltimore). 2016; 95(15):e3273. PMC: 4839808. DOI: 10.1097/MD.0000000000003273. View

14.

Bischiniotis T, Lafaras C, Platogiannis D, Moldovan L, Barbetakis N, Katseas G . Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol. 2005; 46(5):324-9. View

15.

Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J . 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for.... Eur Heart J. 2015; 36(42):2921-2964. PMC: 7539677. DOI: 10.1093/eurheartj/ehv318. View

16.

Swanson N, Mirza I, Wijesinghe N, Devlin G . Primary percutaneous balloon pericardiotomy for malignant pericardial effusion. Catheter Cardiovasc Interv. 2008; 71(4):504-7. DOI: 10.1002/ccd.21431. View

17.

Wang P, Yang K, Chao J, Liu J, Perng R, Yen S . Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest. 2000; 118(3):744-9. DOI: 10.1378/chest.118.3.744. View

18.

Ristic A, Imazio M, Adler Y, Anastasakis A, Badano L, Brucato A . Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2014; 35(34):2279-84. DOI: 10.1093/eurheartj/ehu217. View

19.

Martinoni A, Cipolla C, Civelli M, Cardinale D, Lamantia G, Colleoni M . Intrapericardial treatment of neoplastic pericardial effusions. Herz. 2001; 25(8):787-93. DOI: 10.1007/pl00001998. View

20.

Rodriguez Munoz D, Asteggiano R, Galderisi M, Habib G, Lenihan D, Lyon A . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of.... Eur J Heart Fail. 2016; 19(1):9-42. DOI: 10.1002/ejhf.654. View